Packages (Simulation)
Reagent Preparation
Image (I)
Certificate
Mini Samples ELISA Kit for Colony Stimulating Factor 3, Granulocyte (GCSF)
CSF3; G-CSF; Granulocyte Colony Stimulating Factor; Pluripoietin; Filgrastim; Lenograstim
- Product No.MEA042Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample Typen/a
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Rangen/a
- Sensitivityn/a
- Downloadn/a
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 365
For more details, please contact local distributors! US$ 522 US$ 2349 US$ 4437 US$ 36540
Specificity
This assay has high sensitivity and excellent specificity for detection of Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF).
No significant cross-reactivity or interference between Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) and the recovery rates were calculated by comparing the measured value to the expected amount of Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 93-104 | 96 |
EDTA plasma(n=5) | 85-92 | 88 |
heparin plasma(n=5) | 83-97 | 86 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Mini Samples Colony Stimulating Factor 3, Granulocyte (GCSF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 92-105% | 81-90% | 92-101% | 93-101% |
EDTA plasma(n=5) | 94-102% | 95-104% | 89-103% | 88-102% |
heparin plasma(n=5) | 78-95% | 90-103% | 79-101% | 92-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Scientific Reports | The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37Ra Pubmed:26912204 |
International Journal of Clinical and Experimental Pathology | Low-density neutrophils in severe fever with thrombocytopenia syndrome (SFTS) display decreased function to phagocytose SFTS virus and enhanced capacity to synthesize cytokines ISSN:1936-2625/IJCEP0045334 |
International Immunopharmacology | Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice Pubmed: 30974284 |
Mol Immunol | Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis Pubmed:35749835 |